Pharmaceutical MAH Services in Singapore

A Marketing Authorization Holder (MAH) in Singapore is a company, corporate, or legal entity to whom the marketing authorization for a medicinal product (such as pharmaceuticals, therapeutic products or biologicals) is granted by the Health Sciences Authority (HSA). Pharmaceutical MAH Services in Singapore play a central role in ensuring that all products placed on the Singapore market comply with stringent quality, safety, and efficacy requirements. These services are critical for meeting Singapore MAH requirements and maintaining compliance throughout the product lifecycle.

The MAH is responsible for all aspects of the product in the market, including its quality, safety, efficacy, compliance with the terms of registration, local legislation, and all post-market updates.

For foreign manufacturers, appointing a local MAH is mandatory to manage HSA product registration Singapore, regulatory submissions, and post-approval compliance ensuring safe and legal distribution.

What is the Role of the MAH?

In Singapore, The Marketing Authorization Holder (MAH) is the legal entity (registered with Singapore Accounting and Corporate Regulatory Authority (ACRA)) in whose name the marketing authorization is granted.

The MAH is legally responsible for all aspects of the product throughout its lifecycle in the market, including:

• Product Quality and compliance - Maintaining product quality and compliance with the approved terms of the marketing authorization
• Batch Release - Ensuring batch release in accordance with Good Manufacturing Practice (GMP)
• Variation Applications - Implementing updates or changes in line with technical and scientific progress. Submitting notification or approval applications for changes (called “variations”) to the product (e.g., formula, labeling, manufacturing process)
• Vigilance and Reporting - Handling pharmacovigilance (collection and reporting of adverse effects). Keeping up to date with Regulatory requirements and promptly communicating any issues to the HSA

The MAH is therefore central to post-market surveillance, lifecycle management, and Regulatory maintenance.

Key Regulatory Requirements for MAHs in Singapore

• Physical Presence and Accountability:
  • The MAH must be physically located in Singapore or subject to Singaporean laws
  • The MAH holds the product registration license and is responsible for complying with the Health Products Act and Medicines Act
  • The MAH handles all communications with the HSA and must maintain robust record-keeping and compliance systems.
• Scope of Responsibility:
  • The MAH ensures that the product, as approved by the HSA, is manufactured, tested, stored, and distributed according to the agreed specifications and local regulations.
  • Any amendments to the product, manufacturing, labeling, pharmacovigilance must be processed and approved as required.
• Variation Applications:
  • Changes to the product after registration (known as “variations”) are classified as major or minor. Applications must be submitted to HSA:
  • Major variations (MaV): Significant changes affecting product safety, efficacy, or quality (require detailed data).
  • Minor variations (MiV – PA and MiV – N): Minor changes that require prior approval and administrative updates or changes with minimal or no impact.
• Legal Documents and Authorizations:
  • The MAH’s name and address appear on the approved product documentation and patient information leaflets.
  • A formal Letter of Authorization (LoA) must be provided if the MAH acts on behalf of an overseas product owner or manufacturer, establishing clear responsibility and the local MAH’s authority and liability.
• Product Vigilance and Amendments:
  • The MAH is responsible for:
  • Adverse drug reaction (ADR) or product defects reporting in Singapore
  • Safety updates and periodic safety reports
  • Risk management activities
  • Regulatory safety amendments when required by HSA
  • This ensures continuous product safety monitoring in the Singapore market.
• Quality, Safety, and GMP Compliance:
  • The MAH must confirm that each product batch released in Singapore is consistent with GMP and the marketing authorization.
  • There must be ongoing access to qualified personnel (“Authorised Person”) for batch release certification.

Practical Aspects of MAH Services

Companies engaging MAH services in Singapore typically require support with:

• Regulatory submissions: Preparation and management of applications for product registration, renewals, amendments, and post-approval changes.
• Liaison with HSA: Application to register a product as MAH is made using HSA’s PRISM system. Acting as the primary contact for product-related queries and Regulatory actions.
• Compliance monitoring: Ensuring continual adherence to local and ASEAN regulations.
• Market recall: Initiating and coordinating product withdrawal if safety or quality concerns arise.
• Advertising and Labelling: Ensuring promotional materials, labelling, and packaging comply with the regulations.

Conclusion 

Pharmaceutical MAH Services in Singapore are essential for ensuring Regulatory compliance, product safety, and successful market access. From managing HSA product registration Singapore to meeting evolving Singapore MAH requirements, a compliant MAH structure is critical.

Partnering with experienced providers like Freyr helps streamline MAH services, ensuring efficient submissions, ongoing compliance, and sustained market presence in Singapore.